Expertise in
12
conditions

Noboru Yamamoto

Tokyo, JP 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
12
conditions
Tokyo, JP 

Overview

Noboru Yamamoto practices in Tokyo, Japan. Mr. Yamamoto is highly rated in 12 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Lithotripsy, and Endoscopy.

His clinical research consists of co-authoring 330 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

Tokyo, Japan
Other Locations
Chuo, Japan
Tsukiji, 1040045, Japan
Chuo, Japan
St. Luke's International Hospital, Sapporo, Japan
Tsukuba, Japan
Matsudo, 2702232, Japan
Chiba, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors
A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors
Enrollment Status: Recruiting
Publish Date: December 23, 2025
Intervention Type: Drug
Study Drugs: ABBV-CLS-484, Programmed Cell Death-1 (PD-1) Inhibitor
Study Phase: Phase 1
A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors
A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors
A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Phase: Phase 1
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

330 Total Publications

A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.
A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.
Journal: Investigational new drugs
Published: January 15, 2026

Frequently Asked Questions about Noboru Yamamoto

Is Noboru Yamamoto a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Noboru Yamamoto is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Noboru Yamamoto participate in research or clinical trials?

Yes. Noboru Yamamoto has published 330 articles and abstracts on conditions like Lung Cancer. You can view a list of Noboru Yamamoto's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Yamamoto's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 37 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile